Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 385-397 , October 2007

Clinical practice guidelines for severe Alzheimer’s disease

  • Nathan Herrmann

      Affiliations

    • Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Tel.: (416) 480-6133; Fax: (416) 480-6022.
    • ,
  • Serge Gauthier

      Affiliations

    • Alzheimer’s Disease Research Unit, McGill Center for Studies in Aging, and Department of Neurology, McGill University, Montreal, Quebec, Canada
    • ,
  • Paul G. Lysy

      Affiliations

    • Department of Family Medicine, McGill University, Montreal, Quebec, Canada

References 

  1. Boller F, Verny M, Hugonot-Diener L, Saxton J. Clinical features and assessment of severe dementia: a review. Eur J Neurol. 2002;9:125–136
  2. Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc. 2003;51:S305–S313
  3. Voisin T, Reynish E, Portet F, Feldman H, Vellas B. What are the treatment options for patients with severe Alzheimer’s disease?. CNS Drugs. 2004;18:575–583
  4. Farlow MR. Moderate to severe Alzheimer disease: definition and clinical relevance. Neurology. 2005;65:S1–S4
  5. Vellas B, Gauthier S, Allain H, Andrieu S, Aquino JP, Berrut G, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging. 2005;9:330–338
  6. Canadian Study of Health and Aging (Study methods and prevalence of dementia). CMAJ. 1994;150:899–913
  7. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122
  8. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501–509
  9. Hux MJ, O’Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer’s disease and costs of caring. CMAJ. 1998;159:457–465
  10. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry. 1997;12:841–856
  11. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations—a report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol. 1990;43:891–905
  12. Folstein MF, Folstein SE, McHugh PR. ”Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  13. Reisberg B, Sclan G, Franssen EH, Klugger A, Ferris S. Dementia staging in chronic care populations. Alzheimer Disease Related Disorders. 1944;8:S188–S205
  14. Ferris SH, Yan B. Differential diagnosis and clinical assessment of patients with severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17(Suppl 3):S92–S95
  15. Feldman HH, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology. 2005;65:S10–S17
  16. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136–1139
  17. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24:637–639
  18. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(Suppl 1):173–178
  19. Solomon PR, Adams FA, Groccia ME, DeVeaux R, Growdon JH, Pendlebury WW. Correlational analysis of five commonly used measures of mental status/functional abilities in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13:147–150
  20. Saxton J, McGonigle-Gibson G, Swihart A, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assessment: J Consulting Clin Psychology. 1990;2:2
  21. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41–45
  22. Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry. 2005;13:999–1005
  23. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57:613–620
  24. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590–1599
  25. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341
  26. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324
  27. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33–S39
  28. Galansko DR, Schmitt FA, Jin S. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s disease. Neurobiol Aging. 2000;21:S168
  29. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther. 1999;53:471–481
  30. Katz S, Akpom CA. 12: Index of ADL. Med Care. 1976;14:116–118
  31. Cohen-Mansfield J, Reisberg B, Bonnema J, Berg L, Dastoor DP, Pfeffer RI, et al. Staging methods for the assessment of dementia: perspectives. J Clin Psychiatry. 1996;57:190–198
  32. Reisberg B, Franssen EH, Bobinski M, Auer S, Monteiro I, Boksay I, et al. Overview of methodologic issues for pharmacologic trials in mild, moderate, and severe Alzheimer’s disease. Int Psychogeriatr. 1996;8:159–193
  33. Overall JE, Scott J, Rhoades HM, Lesser J. Empirical scaling of the stages of cognitive decline in senile dementia. J Geriatr Psychiatry Neurol. 1990;3:212–220
  34. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2003;15:346–353
  35. Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, et al. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75–83
  36. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer’s disease. J Gerontol B Psychol Sci Soc Sci. 2000;55:S2–S13
  37. Coen RF, Swanwick GR, O’Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:331–336
  38. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer’s disease. Int J Geriatr Psychiatry. 1998;13:248–256
  39. Miller TP, Tinklenberg JR, Brooks JO, Fenn HH, Yesavage JA. Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 1993;6:235–238
  40. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878–885
  41. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429–434
  42. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266–1272
  43. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology. 1992;42:1689–1696
  44. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord. 1988;2:342–355
  45. Chenoweth B, Spencer B. Dementia: the experience of family caregivers. Gerontologist. 1986;26:267–272
  46. Weiner MF, Koss E, Wild KV, Folks DG, Tariot P, Luszczynska H, et al. Measures of psychiatric symptoms in Alzheimer patients: a review. Alzheimer Dis Assoc Disord. 1996;10:20–30
  47. Cummings JL. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease. Neurology. 2005;65:S18–S24
  48. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  49. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271–284
  50. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly (I: a conceptual review). J Am Geriatr Soc. 1986;34:711–721
  51. Teresi J, Abrams R, Holmes D, Ramirez M, Eimicke J. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol. 2001;36:613–620
  52. Nilsson K, Palmstierna T, Wistedt B. Aggressive behavior in hospitalized psychogeriatric patients. Acta Psychiatr Scand. 1988;78:172–175
  53. Souren LE, Franssen EH, Reisberg B. Contractures and loss of function in patients with Alzheimer’s disease. J Am Geriatr Soc. 1995;43:650–655
  54. Auer SR, Sclan SG, Yaffee RA, Reisberg B. The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc. 1994;42:1266–1272
  55. O’Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45–52
  56. Thomas P, Ingrand P, Lalloue F, Hazif-Thomas C, Billon R, Vieban F, et al. Reasons of informal caregivers for institutionalizing dementia patients previously living at home: the Pixel study. Int J Geriatr Psychiatry. 2004;19:127–135
  57. Gillick M, Berkman S, Cullen L. A patient-centered approach to advance medical planning in the nursing home. J Am Geriatr Soc. 1999;47:227–230
  58. Sampson EL, Ritchie CW, Lai R, Raven PW, Blanchard MR. A systematic review of the scientific evidence for the efficacy of a palliative care approach in advanced dementia. Int Psychogeriatr. 2005;17:31–40
  59. Lyness JM. End-of-life care: issues relevant to the geriatric psychiatrist. Am J Geriatr Psychiatry. 2004;12:457–472
  60. Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. J Gen Intern Med. 2004;19:1057–1063
  61. Scherder E, Oosterman J, Swaab D, Herr K, Ooms M, Ribbe M, et al. Recent developments in pain in dementia. BMJ. 2005;330:461–464
  62. Magri F, Borza A, del Vecchio S, Chytiris S, Cuzzoni G, Busconi L, et al. Nutritional assessment of demented patients: a descriptive study. Aging Clin Exp Res. 2003;15:148–153
  63. Allen NH, Burns A, Newton V, Hickson F, Ramsden R, Rogers J, et al. The effects of improving hearing in dementia. Age Ageing. 2003;32:189–193
  64. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62:1984–1989
  65. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, et al. Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol. 1999;56:1254–1261
  66. Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13:5–21
  67. Herrmann N, Lanctot KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16:261–276
  68. Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439–453
  69. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry. 1999;14:3–47
  70. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401–1406
  71. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145–155
  72. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ. 2003;169:557–564
  73. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–216
  74. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214–219
  75. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. International Journal of Geriatric Psychopharmacology. 1998;1:S26–S34
  76. Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S. Galantamine provides broad benefits in patients with ’advanced moderate’ Alzheimer’s disease (MMSE < or = 12) for up to six months. Int J Clin Pract. 2002;56:509–514
  77. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with ‘advanced moderate’ Alzheimer’s disease for at least 12 months. Dement Geriatr Cogn Disord. 2003;15:79–87
  78. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Leni JR, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20:559–569
  79. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ. 2005;330:874
  80. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057–1065
  81. Hogan DB. Donepezil for severe Alzheimer’s disease. Lancet. 2006;367:1031–1032
  82. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits?. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:705–712
  83. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:243–249
  84. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005;21:1317–1327
  85. Edwards K, Koumaras B, Chen M, Gunay I, Mirski D. Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer’s disease. Clin Drug Invest. 2005;25:507–515
  86. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135–146
  87. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry. 2004;19:919–925
  88. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459–464
  89. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–1222
  90. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;160:S1–S15
  91. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  92. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46
  93. Kiely DK, Morris JN, Algase DL. Resident characteristics associated with wandering in nursing homes. Int J Geriatr Psychiatry. 2000;15:1013–1020
  94. Cohen-Mansfield J, Billig N, Lipson S, Rosenthan AS, Pawlson LG. Medical correlates of agitation in nursing home residents. Gerontology. 1990;36:150–158
  95. Learoyd BM. Psychotropic drugs and the elderly patient. Med J Aust. 1972;1:1131–1133
  96. Lanctot KL, Bowles SK, Herrmann N, Best TS, Naranjo CA. Drugs mimicking dementia: dementia symptoms associated with psychotropic drugs in institutionalised cognitively impaired patients. CNS Drugs. 2000;14:381–390
  97. Corbin SL, Eastwood MR. Sensory deficits and mental disorders of old age: causal or coincidental associations?. Psychol Med. 1986;16:251–256
  98. Horowitz A. The relationship between vision impairment and the assessment of disruptive behaviors among nursing home residents. Gerontologist. 1997;37:620–628
  99. Chapman FM, Dickinson J, McKeith I, Ballard C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer’s disease: treatment implications. Am J Psychiatry. 1999;156:1983–1985
  100. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361–381
  101. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51:1305–1317
  102. Opie J, Rosewarne R, O’Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry. 1999;33:789–799
  103. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry. 2005;20:301–314
  104. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996–2021
  105. Teri L. Behavioral treatment of dementia: an overview. Semin Clin Neuropsychiatry. 1997;2:100–101
  106. Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003;183:248–254
  107. Forbes D, Morgan DG, Bangma J, Peacock S, Pelletier N, Adamson J. Light therapy for managing sleep, behaviour, and mood disturbances in dementia. Cochrane Database Syst Rev. 2005;2:CD003946
  108. Thorgrimsen L, Spector A, Wiles A, Orrell M. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003;CD003150
  109. Ballard CG, O’Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553–558
  110. Consensus statement on improving the quality of mental health care in US. nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003;51:1287–1298
  111. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159:1733–1740
  112. van Reekum R, Clarke D, Conn D, Herrmann N, Eryavec G, Cohen T, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr. 2002;14:197–210
  113. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65:114–119
  114. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study: the Bergen District Nursing Home Study. J Am Geriatr Soc. 2004;52:1737–1743
  115. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry. 2004;65:1329–1334
  116. Schneider LS, Pollock VELyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553–563
  117. Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry. 1998;59:550–563
  118. Sweet RA. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type. Am J Geriatr Psychiatry. 1996;4:311–319
  119. Caligiuri MP, Rockwell E, Jeste DV. Extrapyramidal side effects in patients with Alzheimer’s disease treated with low-dose neuroleptic medication. Am J Geriatr Psychiatry. 1998;6:75–82
  120. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? (prospective study with necropsy follow up). BMJ. 1997;314:266–270
  121. Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med. 1998;26:1–88
  122. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001;28(Suppl 1):S96–S107
  123. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596–608
  124. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5–104
  125. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial—Risperidone Study Group. J Clin Psychiatry. 1999;60:107–115
  126. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946–955
  127. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16:1156–1162
  128. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134–143
  129. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial—the HGEU Study Group. Arch Gen Psychiatry. 2000;57:968–976
  130. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:115–126
  131. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4:81–93
  132. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke?. CNS Drugs. 2005;19:91–103
  133. Health Canada. Health Canada endorsed important safety information on atypical antipsychotic drugs and dementia. 2005;Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/atyp-antipsycho_hpc_e.html. Accessed May 12
  134. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66:1090–1096
  135. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19:473–482
  136. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113–1115
  137. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445
  138. Schneider LS, Dagerman K, SInsel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943
  139. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Psychotropic medication and stroke outcome. Am J Psychiatry. 2005;162:1027–1028
  140. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry. 2004;12:437–439
  141. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17:429–441
  142. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–2341
  143. Lyketsos CG, Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52:243–252
  144. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–746
  145. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125–128
  146. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460–465
  147. Lawlor BA, Radcliffe J, Molchan SE, Martinez RA, Hill JL, Sunderland T. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry. 1994;9:55–59
  148. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5:60–69
  149. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–1278
  150. Herrmann N, Black SE. Behavioral disturbances in dementia: will the real treatment please stand up?. Neurology. 2000;55:1247–1248
  151. Martinon-Torres G, Fioravanti M, Grimley Evans J. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;CD004990
  152. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc. 1994;42:1160–1166
  153. Cooney C, Mortimer A, Smith A, Newton K, Wrigley M. Carbamazepine use in aggressive behaviour associated with senile dementia. Int J Geriatr Psychiatry. 1996;11:901–905
  154. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61
  155. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider L. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400–405
  156. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58–66
  157. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17:579–585
  158. Tariot PN, Schneider LS, Mintzer JE, Cutler AJ. Safety and tolerability of divalproex sodium in treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind placebo-controlled trial. Curr Ther Res Clin Exp. 2001;62:51–67
  159. Tariot PN, Raman R, Jakimovich L, Schneider L, Porteinsson A, Thomas R, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13:942–949
  160. Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2005;3
  161. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley SM, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494–504
  162. Stern RG, Duffelmeyer ME, Zemishlani Z, Davidson M. The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am. 1991;14:375–384
  163. Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis. 1986;174:290–294
  164. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986;47:423–426
  165. Herrmann N, Lanctot KL, Eryavec G, Khan LR. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer’s disease patients. J Psychopharmacol. 2004;18:215–220
  166. Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19:23–28
  167. Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs. haloperidol: a double-blind trial for agitation in nursing home population with Alzheimer’s disease. Am J Geriatr Psychiatry. 1996;4:263–267
  168. Kyomen HH, Hennen J, Gottlieb GL, Wei JY. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am J Psychiatry. 2002;159:1225–1227
  169. Kyomen HH, Satlin A, Hennen J, Wei JY. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. Am J Geriatr Psychiatry. 1999;7:339–348
  170. Hall KA, Keks NA, O’Connor DW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr. 2005;17:165–178
  171. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913–919
  172. Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Bottomley G, Libow L. Opioid treatment for agitation in patients with advanced dementia. Int J Geriatr Psychiatry. 2003;18:700–705
  173. Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17:1120–1127
  174. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep. 2003;26:893–901

PII: S1552-5260(07)00552-3

doi: 10.1016/j.jalz.2007.07.007

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 385-397 , October 2007

Article Tools